| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Data presented at Digestive Disease Week (DDW) 2024
Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated
PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure
PALI-2108 exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human use in Ulcerative Colitis (UC) patients
Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of UC before year end
Posted In: PALI
